SCHEMBL1015064

SCHEMBL1015064

O=C(CSCC(=O)NC1CCCCCCCCCCC1)Nc1ccc(Cl)cc1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.56
LMNA P02545 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
TDP1 Q9NUW8 1/20 0.54
KMT2A Q03164 5/20 0.53
MEN1 O00255 3/20 0.53
SERPINE1 P05121 2/20 0.52
MITF O75030 1/20 0.51
TSHR P16473 1/20 0.51
KDM4E B2RXH2 2/20 0.51
HSD17B10 Q99714 2/20 0.51
ALDH1A1 P00352 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.49
RAB9A P51151 4/20 0.48
POLB P06746 1/20 0.48
EPHX2 P34913 1/20 0.47
NPC1 O15118 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1013563 0.88 KMT2A (0.53) HPGDLMNASMN1; SMN2TDP1KMT2A
SCHEMBL1015522 0.84 RAB9A (0.55) HPGDLMNASMN1; SMN2KMT2ASERPINE1
SCHEMBL1015323 0.83 SERPINE1 (0.65) HPGDLMNASMN1; SMN2KMT2AMEN1
SCHEMBL495622 0.76 SERPINE1 (0.57) KMT2AMEN1SERPINE1KDM4EHSD17B10
SCHEMBL1015912 0.73 RAB9A (0.55) HPGDLMNASMN1; SMN2TDP1KMT2A
SCHEMBL10144718 0.73 HPGD (0.74) HPGDLMNASMN1; SMN2TDP1KMT2A
SCHEMBL3477479 0.72 RAB9A (0.58) LMNASMN1; SMN2KMT2AMEN1KDM4E
SCHEMBL1013705 0.72 L3MBTL1 (0.64) LMNATDP1KMT2AMEN1SERPINE1
SCHEMBL1463554 0.72 RAB9A (0.67) LMNASMN1; SMN2KMT2AMEN1TSHR
SCHEMBL1015881 0.72 MITF (0.58) HPGDLMNASMN1; SMN2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US claimed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US claimed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP claimed
EP-2990057-B1 PAI-1 INHIBITOR FOR USE IN ENHANCING THE ANTITUMOR EFFECT OF AN ANTITUMOR AGENT IN A PATIENT RENASCIENCE CO LTD (JP) 2019-03-20 EP disclosed
US-10092537-B2 Use for PAI-1 inhibitor RENASCIENCE CO., LTD. (JP) 2018-10-09 US disclosed
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2016-06-09 US disclosed
EP-2990057-A1 NOVEL USE FOR PAI-1 INHIBITOR Renascience Co., Ltd. (JP) 2016-03-02 EP disclosed
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US disclosed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US disclosed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 SERPINE1, SERPINB1, SERPINC1 HPGD 683/4885LMNA 525/4885SMN1; SMN2 2290/4885
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 HPGD 502/4885LMNA 1331/4885SMN1; SMN2 2291/4885
US-10092537-B2 Use for PAI-1 inhibitor SERPINE1, SERPINC1, SERPINB1 HPGD 345/4885LMNA 939/4885SMN1; SMN2 1830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.